Download Poster (525.81 KB)

Publication
  • EHA •
  • 13 June, 2026 •
  • •

Avatrombopag in TPO RA–naive adults in acute, persistent, and chronic phases of ITP: results from the REAL AVA 3.0 retrospective study

Sandhya Panch, Abiola Oladapo, Faizan Sattar, Michael Vredenburg , Sarah Lucht, Emily Bland, Prathamesh Pathak, Bruce Feinberg, Debbie Jiang

Available materials

Poster
Publication
  • EHA •
  • 13 June, 2026 •
  • •

Real-world hemoglobin profiles and transfusion burden in patients with paroxysmal nocturnal hemoglobinuria receiving complement inhibitors: A US claims analysis

Carlos de Castro, Peter Blandino, Fiston Vuvu, Enrico Zanardo, Lynn Huynh, Robert Schell, Nathaniel Downes, Yixin Yang, Mei Sheng Duh, Peter Hillmen

Available materials

Poster
Publication
  • EHA •
  • 12 June, 2026 •
  • •

Impact of protocol mandated dose holds on platelet response durability in pediatric ITP treated with avatrombopag: AVA 301 post hoc analysis

Rachael F. Grace, Göksel Leblebisatan, Yesim Aydinok, Şule Ünal, John Grainger, Amanda Grimes, Michele Lambert, Jessica Zhang, Brian D. Jamieson, Chelsea Bernheisel, Michael Vredenburg , Faizan Sattar

Available materials

Oral Presentation
Publication
  • SOHO •
  • 9 September, 2026 •
  • •

Real-world Treatment Patterns and Outcomes in Patients with Myelofibrosis Treated First-line with Pacritinib or Ruxolitinib

James Rossetti, Douglas Tremblay, Abiola Oladapo, Michael Marrone, Caleb Paydar, Djibril Liassou, Sarah Buckley, Purvi Suthar, Adina Geprifti, Michael Vredenburg , Bruce Feinberg, Naveen Pemmaraju

Publication
  • SOHO •
  • 9 September, 2026 •
  • •

Real-World Use of Pacritinib in Myelofibrosis: Results from the TriNetX Analysis on Patient Characteristics, Treatment Patterns, and Outcomes in Patients with Platelets ≥50×10⁹/L at Initiation (TRIPAC)

Ghaith Abu-Zeinah, Alex Coltoff, Erick Moyneur, Katherine Dea, Michael Marrone, Sara Bruce Wirta, Faizan Sattar, Michael Vredenburg , Andrew Srisuwananukorn

Publication
  • ERA •
  • 4 June, 2026 •
  • •

Decreasing rates of injection site reactions over time: Long-term outcomes across multiple indications support pegcetacoplan for C3G/primary IC-MPGN

Nabil Melhem, Antonio Mastrangelo, Daniel Zecher, Abdallah S Geara, Carla M Nester, Sheena Patel, Liza Alkhori Franzén, Andrew Carrel, Carlos de Castro, Daniel P Gale, Richard J. Kelly

Available materials

Oral Presentation
Publication
  • ASCO •
  • 1 June, 2026 •
  • •

Treatment Patterns and Outcomes in Pacritinib-treated Patients with and higher platelet count: MY-PAC Study

Douglas Tremblay, Abiola Oladapo, Michael Marrone, Puja Aggarwal, Caleb Paydar, Djibril Liassou, Purvi Suthar, Adina Geprifti, Michael Vredenburg , Bruce Feinberg

Sign up for alerts